Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.951215/full |
| _version_ | 1828517832745287680 |
|---|---|
| author | Ikhwan Rinaldi Ikhwan Rinaldi Samuel Pratama Lowilius Wiyono Jeremy Rafael Tandaju Indy Larasati Wardhana Kevin Winston Kevin Winston |
| author_facet | Ikhwan Rinaldi Ikhwan Rinaldi Samuel Pratama Lowilius Wiyono Jeremy Rafael Tandaju Indy Larasati Wardhana Kevin Winston Kevin Winston |
| author_sort | Ikhwan Rinaldi |
| collection | DOAJ |
| description | Patient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies and 1,105 healthy subjects as control were included. After two doses of COVID-19 vaccination, only 60% of cohorts with hematological malignancies were seroconverted compared to healthy controls (RR 0.60; 95%CI 0.50–0.71). A single dose of the vaccine resulted in a significantly lower seroconversion rate (RR 0.30; 95%CI 0.16–0.54). Non-Hodgkin lymphoma cohorts had the lowest rate of seroconversion (RR 0.5; 95%CI 0.35–0.71) and those who received active treatments had lower immunological responses (RR 0.59; 95%CI 0.46–0.75). Antibody titers were lower in cohorts with hematological malignancies without any differences in adverse effects in both groups. In conclusion, cohorts with hematological malignancies showed a lower seroconversion rate and antibody titers after receiving COVID-19 mRNA vaccines. The type of malignancy and the status of treatment had a significant impact on the response to vaccination. The vaccines were shown to be safe for both patients with hematological malignancies and healthy controls. Booster doses and stricter health protocols might be beneficial for patient populations. |
| first_indexed | 2024-12-11T18:46:50Z |
| format | Article |
| id | doaj.art-7e306d1b55204e28a8cb5fdbeeac7ddc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T18:46:50Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7e306d1b55204e28a8cb5fdbeeac7ddc2022-12-22T00:54:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.951215951215Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysisIkhwan Rinaldi0Ikhwan Rinaldi1Samuel Pratama2Lowilius Wiyono3Jeremy Rafael Tandaju4Indy Larasati Wardhana5Kevin Winston6Kevin Winston7Hematology and Medical Oncology Division, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaFaculty of Medicine, University of Indonesia, Jakarta, IndonesiaHospital Medicine, Bhakti Medicare Hospital, Cicurug, Sukabumi, IndonesiaPatient populations, including those with hematological malignancies, have different responses to COVID-19 vaccines. This study aimed to quantitatively analyze the efficacy and safety of COVID-19 mRNA vaccines in patients with hematological malignancies. Studies reporting on the efficacy and safety of COVID-19 mRNA vaccines in cohorts with hematological malignancies compared to healthy controls were systematically searched in four databases. Meta-analysis and subgroup analyses were performed to generate quantitative synthesis. Fifteen studies with 2,055 cohorts with hematological malignancies and 1,105 healthy subjects as control were included. After two doses of COVID-19 vaccination, only 60% of cohorts with hematological malignancies were seroconverted compared to healthy controls (RR 0.60; 95%CI 0.50–0.71). A single dose of the vaccine resulted in a significantly lower seroconversion rate (RR 0.30; 95%CI 0.16–0.54). Non-Hodgkin lymphoma cohorts had the lowest rate of seroconversion (RR 0.5; 95%CI 0.35–0.71) and those who received active treatments had lower immunological responses (RR 0.59; 95%CI 0.46–0.75). Antibody titers were lower in cohorts with hematological malignancies without any differences in adverse effects in both groups. In conclusion, cohorts with hematological malignancies showed a lower seroconversion rate and antibody titers after receiving COVID-19 mRNA vaccines. The type of malignancy and the status of treatment had a significant impact on the response to vaccination. The vaccines were shown to be safe for both patients with hematological malignancies and healthy controls. Booster doses and stricter health protocols might be beneficial for patient populations.https://www.frontiersin.org/articles/10.3389/fonc.2022.951215/fullCOVID-19mRNA vaccinehematologic malignanciesseroconversion ratesantibody titersadverse effects |
| spellingShingle | Ikhwan Rinaldi Ikhwan Rinaldi Samuel Pratama Lowilius Wiyono Jeremy Rafael Tandaju Indy Larasati Wardhana Kevin Winston Kevin Winston Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis Frontiers in Oncology COVID-19 mRNA vaccine hematologic malignancies seroconversion rates antibody titers adverse effects |
| title | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
| title_full | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
| title_fullStr | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
| title_short | Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis |
| title_sort | efficacy and safety profile of covid 19 mrna vaccine in patients with hematological malignancies systematic review and meta analysis |
| topic | COVID-19 mRNA vaccine hematologic malignancies seroconversion rates antibody titers adverse effects |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.951215/full |
| work_keys_str_mv | AT ikhwanrinaldi efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT ikhwanrinaldi efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT samuelpratama efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT lowiliuswiyono efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT jeremyrafaeltandaju efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT indylarasatiwardhana efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT kevinwinston efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis AT kevinwinston efficacyandsafetyprofileofcovid19mrnavaccineinpatientswithhematologicalmalignanciessystematicreviewandmetaanalysis |